Disrupted cartilage products

Patent metadata

Field	Value
Publication number	US-11413373-B2
Application number	US-201414498394-A
Country	US
Kind code	B2
Filing date	Sep 26, 2014
Priority date	Jul 11, 2012
Publication date	Aug 16, 2022
Grant date	Aug 16, 2022

Abstract

This invention provides disrupted cartilage products, methods of manufacturing disrupted cartilage products, and methods of treating a subject comprising administering a cartilage product. The cartilage products are manufactured by a method comprising disrupting a collagen matrix, e.g. to produce a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic.

First claim

What is claimed is:

1. A cryopreserved cartilage product comprising a cryopreserved natural cartilage collagen matrix isolated from a subject,
wherein the natural cartilage collagen matrix is partially digested prior to cryopreservation,
wherein the collagen matrix comprises a plurality of channels,
wherein the collagen matrix contains viable cells embedded within the collagen matrix that are native to the collagen matrix and that were embedded in the collagen matrix when the collagen matrix was isolated from the subject,
wherein at least 70% of the embedded cells native to the collagen matrix are viable in the cryopreserved cartilage product,
wherein the collagen matrix retains the structural and functional properties of natural cartilage,
wherein digestion is limited to an amount that preserves the viability of embedded cells native to the collagen matrix and/or the structural and functional properties of the collagen matrix,
wherein the collagen matrix comprises a plurality of channels and
a radial, a transitional and a tangential layer,
wherein the plurality of channels extend substantially perpendicularly to the radial, transitional or tangential layer,
wherein the plurality of channels extend entirely through the radial, transitional, and the tangential layer, and
wherein the partially digested collagen matrix retains interaction between the collagen matrix and the native cells.

2. The cartilage product of claim 1 , wherein the channels are of the tissue-removal type.

3. The cartilage product of claim 1 , wherein the collagen matrix has a thickness of about 0.2 mm to about 3.0 mm.

4. The cartilage product of claim 1 , wherein the collagen matrix has a thickness of about 1 mm to about 1.55 mm.

5. The cartilage product of claim 1 , further comprising a layer of bone, wherein the layer of bone is native to the collagen matrix.

6. The cartilage product of claim 5 , wherein the layer of bone has a surface area substantially less than that of the collagen matrix.

7. The cartilage product of claim 1 , wherein the plurality of channels are cylindrical.

8. The cartilage product of claim 1 , wherein the collagen matrix comprises a channel density of about 10 to about 500 pores per cm 2 .

9. The cartilage product of claim 1 , wherein the collagen matrix comprises bioactive factors, wherein the bioactive factors are native to the collagen matrix.

10. The cartilage product of claim 5 , wherein the plurality of channels extend into the bone.

11. The cartilage product of claim 5 , wherein the plurality of channels do not extend into the bone.

12. The cartilage product of claim 1 , wherein the viable cells native to the collagen matrix comprise viable chondrocytes.

13. The cartilage product of claim 1 , further comprising a cryopreservation medium.

14. The cartilage product of claim 1 , wherein the cartilage product is devoid of subchondral bone or calcified cartilage.

15. The cartilage product of claim 1 , wherein the cartilage product is depleted of immunogenic cells.

16. The cartilage product of claim 1 , wherein the collagen matrix comprises a channel density of about 10 to about 100 or about 20 to about 60 channels per cm 2 .

17. The cartilage product of claim 1 , wherein the plurality of channels have a diameter of about 0.6 mm to about 1 mm.

18. The cartilage product of claim 1 , wherein the cartilage product does not comprise a substantial amount of macrophages.

Assignees

• Osiris Therapeutics Inc

Inventors

• Yoo Dana Sue
• Kuang Jin-Qiang
• Paden Jaime
• Maxson Scott A
• Danilkovitch Alla
• Lopez Erasmo
• Tom Samson

Classifications

• A61L27/3654

  Cartilage, e.g. meniscus · CPC title

• A61L27/3817

  Cartilage-forming cells, e.g. pre-chondrocytes · CPC title

• A61K35/32

  Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane · CPC title

• A61L27/56

  Porous materials, {e.g. foams or sponges} · CPC title

• A61L27/24

  Collagen · CPC title